ECSP056006A - Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas - Google Patents

Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas

Info

Publication number
ECSP056006A
ECSP056006A EC2005006006A ECSP056006A ECSP056006A EC SP056006 A ECSP056006 A EC SP056006A EC 2005006006 A EC2005006006 A EC 2005006006A EC SP056006 A ECSP056006 A EC SP056006A EC SP056006 A ECSP056006 A EC SP056006A
Authority
EC
Ecuador
Prior art keywords
rapamycin
inflammatory
derivative
treatment
pharmaceutical compositions
Prior art date
Application number
EC2005006006A
Other languages
English (en)
Inventor
Henrietta Moore
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33032928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP056006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0306070A external-priority patent/GB0306070D0/en
Priority claimed from GB0306868A external-priority patent/GB0306868D0/en
Priority claimed from GB0319226A external-priority patent/GB0319226D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP056006A publication Critical patent/ECSP056006A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden en combinación rapamicina o un derivado de rapamicina y un compuesto de la fórmula I, por ejemplo, útiles para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas, incluyendo enfermedades autoinmunes.
EC2005006006A 2003-03-17 2005-09-08 Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas ECSP056006A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0306070A GB0306070D0 (en) 2003-03-17 2003-03-17 Organic compounds
GB0306868A GB0306868D0 (en) 2003-03-25 2003-03-25 Organic compounds
GB0319226A GB0319226D0 (en) 2003-08-15 2003-08-15 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP056006A true ECSP056006A (es) 2006-01-27

Family

ID=33032928

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006006A ECSP056006A (es) 2003-03-17 2005-09-08 Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas

Country Status (25)

Country Link
US (1) US20060154952A1 (es)
EP (1) EP1608368B8 (es)
JP (1) JP2006515017A (es)
KR (1) KR100855140B1 (es)
AR (1) AR043504A1 (es)
AT (1) ATE409479T1 (es)
AU (1) AU2004222563B2 (es)
BR (1) BRPI0408423A (es)
CA (2) CA2517671A1 (es)
CL (1) CL2004000535A1 (es)
DE (1) DE602004016830D1 (es)
EC (1) ECSP056006A (es)
ES (1) ES2315648T3 (es)
HR (1) HRP20050800A2 (es)
IS (1) IS8028A (es)
MA (1) MA27671A1 (es)
MX (1) MXPA05009934A (es)
MY (1) MY137868A (es)
NO (1) NO20054778L (es)
PE (1) PE20050313A1 (es)
PL (1) PL1608368T3 (es)
PT (1) PT1608368E (es)
TN (1) TNSN05197A1 (es)
TW (2) TW200503703A (es)
WO (1) WO2004082681A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2585840A1 (en) * 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2010206840B2 (en) * 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
RU2449806C1 (ru) * 2010-11-30 2012-05-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения красного плоского лишая слизистой оболочки полости рта
DK2948134T3 (da) 2013-01-24 2020-06-02 Palvella Therapeutics Inc Sammensætninger til transdermal indgivelse af mtor-inhibitorer
KR102256576B1 (ko) 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
PL3125875T3 (pl) * 2014-04-04 2023-11-20 AI Therapeutics, Inc. Nadający się do inhalacji preparat rapamycyny do leczenia stanów związanych z wiekiem
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
IL283764B2 (en) 2015-04-10 2024-01-01 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
CN110520097B (zh) 2017-01-06 2023-10-27 帕尔维拉治疗股份有限公司 Mtor抑制剂的无水组合物及其使用方法
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6239124B1 (en) * 1996-07-30 2001-05-29 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
EP1389108A2 (en) * 2001-05-09 2004-02-18 Novartis AG Methods for selective immunomodulation using pimecrolimus
AU2003205586A1 (en) * 2002-01-10 2003-07-24 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
EP1501566B1 (de) * 2002-05-09 2008-08-13 Hemoteq AG Hemokompatibel beschichtete medizinprodukte, deren herstellung und verwendung

Also Published As

Publication number Publication date
JP2006515017A (ja) 2006-05-18
WO2004082681B1 (en) 2004-11-25
IS8028A (is) 2005-09-15
AR043504A1 (es) 2005-08-03
MA27671A1 (fr) 2005-12-01
MY137868A (en) 2009-03-31
AU2004222563A1 (en) 2004-09-30
DE602004016830D1 (de) 2008-11-13
PT1608368E (pt) 2009-01-27
ES2315648T3 (es) 2009-04-01
EP1608368B1 (en) 2008-10-01
CL2004000535A1 (es) 2005-01-14
MXPA05009934A (es) 2006-03-21
NO20054778D0 (no) 2005-10-17
PL1608368T3 (pl) 2009-03-31
NO20054778L (no) 2005-12-19
AU2004222563B2 (en) 2006-11-02
WO2004082681A1 (en) 2004-09-30
CA2517671A1 (en) 2004-09-30
TW200503703A (en) 2005-02-01
PE20050313A1 (es) 2005-06-14
HK1086743A1 (en) 2006-09-29
CA2633287A1 (en) 2004-09-30
KR100855140B1 (ko) 2008-08-28
TW200835484A (en) 2008-09-01
KR20050110023A (ko) 2005-11-22
ATE409479T1 (de) 2008-10-15
TNSN05197A1 (en) 2007-06-11
EP1608368A1 (en) 2005-12-28
HRP20050800A2 (en) 2006-11-30
BRPI0408423A (pt) 2006-03-21
EP1608368B8 (en) 2009-06-10
US20060154952A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
HN2012001162A (es) Triazolopiridinas
SV2005001973A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
ECSP066717A (es) Compuestos de quinolina sustituidos
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
ECSP099371A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY31457A1 (es) Derivados acidos de cicloalquilamino
AR050717A1 (es) Composiciones farmaceuticas
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
ECSP056006A (es) Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas
UY29170A1 (es) Adeninas sustituidas y usos de las mismas
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
NI200300045A (es) Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
ATE538124T1 (de) Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
GT200500310A (es) Compuestos organicos
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
ATE474574T1 (de) Imidazoazephinonverbindungen
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
BRPI0417205A (pt) composições farmacêuticas
UY29308A1 (es) Derivado de quinolina, su uso, preparación y medicamento que lo contiene